Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individ...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-08-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/10/16/5403 |
id |
doaj-b3b9f4a41694455eb0bc96deb80ae6c9 |
---|---|
record_format |
Article |
spelling |
doaj-b3b9f4a41694455eb0bc96deb80ae6c92020-11-25T03:52:53ZengMDPI AGApplied Sciences2076-34172020-08-01105403540310.3390/app10165403Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with LenvatinibYurika Kotoh0Issei Saeki1Takahiro Yamasaki2Ryo Sasaki3Norikazu Tanabe4Takashi Oono5Takashi Matsuda6Takuro Hisanaga7Toshihiko Matsumoto8Isao Hidaka9Tsuyoshi Ishikawa10Taro Takami11Isao Sakaida12Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanDepartment of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi 755-8505, JapanPrevious studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as <26 and <18 kg and SMI <42 and SMI <38 cm<sup>2</sup>/m<sup>2</sup> in men and women, respectively. Sarcopenia was defined as having low handgrip strength and muscle depletion. Multivariate analysis identified modified albumin–bilirubin grade 1–2a (<i>p</i> = 0.010), Barcelona Clinic Liver Cancer stage A–B (<i>p</i> = 0.011), and absence of low handgrip strength (<i>p</i> = 0.015) as favorable prognostic factors for survival. Furthermore, sarcopenia was an independent significant prognostic factor for survival. Time to treatment failure was associated with handgrip strength and sarcopenia. Our findings suggest that handgrip strength may be a useful marker of clinical outcomes in HCC patients treated with lenvatinib.https://www.mdpi.com/2076-3417/10/16/5403hepatocellular carcinomahandgrip strengthlenvatinibskeletal musclesurvivaltime to treatment failure |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Yurika Kotoh Issei Saeki Takahiro Yamasaki Ryo Sasaki Norikazu Tanabe Takashi Oono Takashi Matsuda Takuro Hisanaga Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Taro Takami Isao Sakaida |
spellingShingle |
Yurika Kotoh Issei Saeki Takahiro Yamasaki Ryo Sasaki Norikazu Tanabe Takashi Oono Takashi Matsuda Takuro Hisanaga Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Taro Takami Isao Sakaida Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib Applied Sciences hepatocellular carcinoma handgrip strength lenvatinib skeletal muscle survival time to treatment failure |
author_facet |
Yurika Kotoh Issei Saeki Takahiro Yamasaki Ryo Sasaki Norikazu Tanabe Takashi Oono Takashi Matsuda Takuro Hisanaga Toshihiko Matsumoto Isao Hidaka Tsuyoshi Ishikawa Taro Takami Isao Sakaida |
author_sort |
Yurika Kotoh |
title |
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib |
title_short |
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib |
title_full |
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib |
title_fullStr |
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib |
title_full_unstemmed |
Effect of Handgrip Strength on Clinical Outcomes of Patients with Hepatocellular Carcinoma Treated with Lenvatinib |
title_sort |
effect of handgrip strength on clinical outcomes of patients with hepatocellular carcinoma treated with lenvatinib |
publisher |
MDPI AG |
series |
Applied Sciences |
issn |
2076-3417 |
publishDate |
2020-08-01 |
description |
Previous studies have reported prognostic factors for hepatocellular carcinoma (HCC) patients receiving lenvatinib; however, no studies have evaluated the effects of both handgrip strength and skeletal muscle mass on the clinical outcomes. Therefore, this retrospective study investigated the individual effect of handgrip strength, skeletal muscle mass, and sarcopenia on clinical outcomes of 53 HCC patients treated with lenvatinib. Before receiving lenvatinib, handgrip strength and skeletal muscle index (SMI) were measured. Low handgrip strength and muscle depletion were defined as <26 and <18 kg and SMI <42 and SMI <38 cm<sup>2</sup>/m<sup>2</sup> in men and women, respectively. Sarcopenia was defined as having low handgrip strength and muscle depletion. Multivariate analysis identified modified albumin–bilirubin grade 1–2a (<i>p</i> = 0.010), Barcelona Clinic Liver Cancer stage A–B (<i>p</i> = 0.011), and absence of low handgrip strength (<i>p</i> = 0.015) as favorable prognostic factors for survival. Furthermore, sarcopenia was an independent significant prognostic factor for survival. Time to treatment failure was associated with handgrip strength and sarcopenia. Our findings suggest that handgrip strength may be a useful marker of clinical outcomes in HCC patients treated with lenvatinib. |
topic |
hepatocellular carcinoma handgrip strength lenvatinib skeletal muscle survival time to treatment failure |
url |
https://www.mdpi.com/2076-3417/10/16/5403 |
work_keys_str_mv |
AT yurikakotoh effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT isseisaeki effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT takahiroyamasaki effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT ryosasaki effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT norikazutanabe effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT takashioono effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT takashimatsuda effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT takurohisanaga effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT toshihikomatsumoto effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT isaohidaka effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT tsuyoshiishikawa effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT tarotakami effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib AT isaosakaida effectofhandgripstrengthonclinicaloutcomesofpatientswithhepatocellularcarcinomatreatedwithlenvatinib |
_version_ |
1724480342175252480 |